- Home
- WHF vs SGMO Comparison
WHF vs SGMO Comparison
Compare WHF & SGMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WHF | SGMO |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | United States | United States |
| Employees | 3 | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.2M | 141.2M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | WHF | SGMO |
|---|---|---|
| Price | $7.32 | $0.35 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.75 | $7.00 |
| AVG Volume (30 Days) | 122.7K | ★ 4.6M |
| Earning Date | 03-02-2026 | 05-11-2026 |
| Dividend Yield | ★ 14.68% | N/A |
| EPS Growth | N/A | ★ 66.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,567,000.00 |
| Revenue This Year | N/A | $4.79 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.35 | ★ N/A |
| Revenue Growth | N/A | ★ 88.60 |
| 52 Week Low | $6.07 | $0.32 |
| 52 Week High | $9.95 | $0.88 |
Technical Indicators
Market Signals| Indicator | WHF | SGMO |
|---|---|---|
| Relative Strength Index (RSI) | 59.38 | 44.06 |
| Support Level | $6.79 | N/A |
| Resistance Level | $7.73 | $0.56 |
| Average True Range (ATR) | 0.22 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 59.75 | 35.76 |
Price Performance
Historical ComparisonAbout WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About SGMO Sangamo Therapeutics Inc.
Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its pipeline products include the Priority Neurology Pipeline offers Chronic Neuropathic Pain, Prion Disease, and Neurology; Partnered Programs offer Hemophilia A, Oncology, ALS/FTD, and Huntington's Disease; and Other Pipelines include Fabry Disease, Renal Transplant, Inflammatory Bowel Disease, and Multiple Sclerosis.